Abstract
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abscess model in the rat. Efficacies corresponded to minimum inhibitory concentrations (MICs) measured in vitro and were consistent with drug exposures modelled from pharmacokinetics in infected animals. The ceftazidime, ceftazidime-avibactam and meropenem control treatments were effective in the rat abscess model against the susceptible strain, whereas only ceftazidime-avibactam was effective against K. pneumoniae harbouring blaKPC-2.
Keywords:
Abscess infection; Ceftazidime–avibactam; KPC; Klebsiella pneumoniae; Rat pharmacokinetics.
MeSH terms
-
Abdominal Abscess / drug therapy*
-
Abdominal Abscess / metabolism
-
Abdominal Abscess / microbiology
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Azabicyclo Compounds / pharmacology
-
Bacterial Proteins / metabolism*
-
Ceftazidime / pharmacology
-
Disease Models, Animal*
-
Drug Combinations
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / metabolism
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / isolation & purification
-
Klebsiella pneumoniae / metabolism
-
Meropenem
-
Microbial Sensitivity Tests
-
Rats
-
Thienamycins / pharmacology
-
beta-Lactam Resistance*
-
beta-Lactamases
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Bacterial Proteins
-
Drug Combinations
-
Thienamycins
-
avibactam, ceftazidime drug combination
-
Ceftazidime
-
beta-Lactamases
-
Meropenem